Last reviewed · How we verify
islet body
At a glance
| Generic name | islet body |
|---|---|
| Sponsor | Allife Medical Science and Technology Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Improving Islet Transplantation Outcomes With Gastrin for Type I Diabetes (PHASE1, PHASE2)
- Islet Cell Transplant for Type 1 Diabetes (PHASE2)
- Islet Transplant for Type 1 or Surgical Diabetes
- Allogeneic Islet Cells Transplanted Onto the Omentum (PHASE1, PHASE2)
- SGLT2 Inhibitors in Treating Patients With PCOS (NA)
- Current Status of Islet Alpha Cell Function in Patients with Type 2 Diabetes (PHASE3)
- Intra-Portal Alone Versus Intra- and Extra-Portal Transplantation of Pancreatic Islets After Total Pancreatectomy for Chronic Pancreatitis (NA)
- Islet Allotransplantation in Type 1 Diabetes (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- islet body CI brief — competitive landscape report
- islet body updates RSS · CI watch RSS
- Allife Medical Science and Technology Co., Ltd. portfolio CI